These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 14993792)
1. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model. Zhou X; Qian X; Zhao Q; Lu Y; Xiong M Biol Pharm Bull; 2004 Mar; 27(3):303-7. PubMed ID: 14993792 [TBL] [Abstract][Full Text] [Related]
2. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676 [TBL] [Abstract][Full Text] [Related]
3. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Li YL; Qiu XH; Shen C; Liu JN; Zhang J Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127 [TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939 [TBL] [Abstract][Full Text] [Related]
5. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419 [TBL] [Abstract][Full Text] [Related]
6. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Daemen T; Regts J; Holtrop M; Wilschut J Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066 [TBL] [Abstract][Full Text] [Related]
7. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X. Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model. Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134 [TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Cassetti MC; McElhiney SP; Shahabi V; Pullen JK; Le Poole IC; Eiben GL; Smith LR; Kast WM Vaccine; 2004 Jan; 22(3-4):520-7. PubMed ID: 14670335 [TBL] [Abstract][Full Text] [Related]
11. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice]. Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859 [TBL] [Abstract][Full Text] [Related]
12. [Construction of recombinant vaccina virus of HPV16 and its antitumor effect]. Huang W; Tian HW; Ren J; Fan JT; Zhao L; Ruan L Ai Zheng; 2005 Jul; 24(7):817-22. PubMed ID: 16004807 [TBL] [Abstract][Full Text] [Related]
13. [High expression of HPV16L2N120E7E6 fusion protein in E. coli and its inhibitory effect on tumor growth in mice]. Zhao L; Gao M; Gao J; Ren J; Zhang H; Tian HW; Tan WJ; Ruan L Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):810-5. PubMed ID: 23291127 [TBL] [Abstract][Full Text] [Related]
14. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328 [TBL] [Abstract][Full Text] [Related]
15. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects. Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440 [TBL] [Abstract][Full Text] [Related]
16. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine]. Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710 [TBL] [Abstract][Full Text] [Related]
17. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411 [TBL] [Abstract][Full Text] [Related]
18. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747 [TBL] [Abstract][Full Text] [Related]